PT3310805T - Proteínas de fusão pd-1-cd28 e a sua utilização em medicina - Google Patents
Proteínas de fusão pd-1-cd28 e a sua utilização em medicinaInfo
- Publication number
- PT3310805T PT3310805T PT167368026T PT16736802T PT3310805T PT 3310805 T PT3310805 T PT 3310805T PT 167368026 T PT167368026 T PT 167368026T PT 16736802 T PT16736802 T PT 16736802T PT 3310805 T PT3310805 T PT 3310805T
- Authority
- PT
- Portugal
- Prior art keywords
- medicine
- fusion proteins
- fusion
- proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15172913 | 2015-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3310805T true PT3310805T (pt) | 2021-05-19 |
Family
ID=53476720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT167368026T PT3310805T (pt) | 2015-06-19 | 2016-06-20 | Proteínas de fusão pd-1-cd28 e a sua utilização em medicina |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11192935B2 (enExample) |
| EP (3) | EP3909972B1 (enExample) |
| JP (3) | JP7085988B2 (enExample) |
| CN (3) | CN115927474A (enExample) |
| AU (1) | AU2016277883B2 (enExample) |
| CA (1) | CA2989949A1 (enExample) |
| DK (2) | DK3909972T5 (enExample) |
| ES (2) | ES2870174T3 (enExample) |
| FI (1) | FI3909972T3 (enExample) |
| HU (1) | HUE054201T2 (enExample) |
| PL (1) | PL3310805T3 (enExample) |
| PT (1) | PT3310805T (enExample) |
| WO (1) | WO2016203048A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107531805A (zh) | 2015-03-05 | 2018-01-02 | 弗雷德哈钦森癌症研究中心 | 免疫调节融合蛋白及其用途 |
| BR112017024757A2 (pt) | 2015-05-18 | 2018-11-13 | TCR2 Therapeutics Inc. | composições e métodos para reprogramação de tcr utilizando proteínas de fusão |
| CN115927474A (zh) | 2015-06-19 | 2023-04-07 | 塞巴斯蒂安·科博尔德 | Pd-1-cd28融合蛋白及其在医学中的用途 |
| US20180185434A1 (en) * | 2015-06-29 | 2018-07-05 | The Johns Hopkins University | Immune checkpoint chimeric antigen receptors therapy |
| CN105331585A (zh) * | 2015-11-13 | 2016-02-17 | 科济生物医药（上海）有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| WO2017162797A1 (en) * | 2016-03-23 | 2017-09-28 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of pd-1 and 4-1bb |
| CN107523545A (zh) * | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达抗体的杀伤性细胞及其用途 |
| AU2017291262A1 (en) * | 2016-06-30 | 2019-01-03 | F. Hoffmann-La Roche Ag | Improved adoptive T-cell therapy |
| WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| MX2019003899A (es) | 2016-10-07 | 2019-08-14 | Tcr2 Therapeutics Inc | Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion. |
| AU2017363311A1 (en) | 2016-11-22 | 2019-06-13 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| JP2020513754A (ja) * | 2016-12-21 | 2020-05-21 | ティーシーアール２ セラピューティクス インク． | がん治療用に操作されたｔ細胞 |
| EP3574005B1 (en) * | 2017-01-26 | 2021-12-15 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
| MX2019010812A (es) | 2017-03-17 | 2019-12-11 | Hutchinson Fred Cancer Res | Proteinas de fusion inmunomoduladoras y sus usos. |
| WO2019173324A1 (en) * | 2018-03-06 | 2019-09-12 | The Trustees Of The University Of Pennsylvania | Prostate-specific membrane antigen cars and methods of use thereof |
| CN108727504B (zh) * | 2018-04-16 | 2021-08-27 | 泉州向日葵生物科技有限公司 | 一种ifn与抗pd-l1抗体的融合蛋白及其应用 |
| CN111606999B (zh) * | 2019-02-26 | 2022-09-06 | 南京惟亚德生物医药有限公司 | 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用 |
| JP7654557B2 (ja) * | 2019-03-27 | 2025-04-01 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Ｔｎ－ＭＵＣ１キメラ抗原受容体（ＣＡＲ）Ｔ細胞療法 |
| EP3999079A4 (en) * | 2019-07-19 | 2024-04-03 | Memorial Sloan Kettering Cancer Center | Fusion polypeptide for immunotherapy |
| CN113832111A (zh) * | 2020-06-23 | 2021-12-24 | 南京大学 | 一种类外泌体技术用于制备新型溶瘤病毒的方法 |
| CN113832114A (zh) * | 2020-06-23 | 2021-12-24 | 南京大学 | 一种新型溶瘤腺病毒EM/VSV-G Ad5-P及其在制备抗肿瘤药物中的应用 |
| EP4305174A4 (en) * | 2021-03-10 | 2025-04-30 | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University | REPORTER CELLS EXPRESSING CHIMERIC POLYPEPTIDES TO DETERMINE THE PRESENCE AND/OR ACTIVITY OF IMMUNE CHECKPOINT MOLECULES |
| CN115197314B (zh) * | 2021-04-11 | 2025-08-19 | 中国科学院分子细胞科学卓越创新中心 | 一种pd1变体及其用途 |
| JP2024519945A (ja) * | 2021-05-20 | 2024-05-21 | アチェロイス バイオファーマ，インク． | 免疫チェックポイント多価粒子の組成物、および使用方法 |
| WO2023235479A1 (en) * | 2022-06-02 | 2023-12-07 | TCR2 Therapeutics Inc. | Compositions and methods for treating cancer |
| WO2024107577A2 (en) * | 2022-11-14 | 2024-05-23 | Achelois Biopharma, Inc. | Immune checkpoint multivalent particles compositions and methods of use |
| WO2025212859A1 (en) * | 2024-04-03 | 2025-10-09 | Solid Biosciences, Inc. | Methods and constructs for increasing solid organ transplant survival |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19822115B4 (de) | 1998-05-08 | 2004-04-08 | Heinrich-Pette-Institut | Retrovirale Gentransfervektoren |
| CN101287831B (zh) | 2005-09-13 | 2013-05-15 | 国立大学法人三重大学 | T细胞受体和编码该受体的核酸 |
| WO2010012829A1 (en) | 2008-07-31 | 2010-02-04 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Her2/neu specific t cell receptors |
| ZA200807283B (en) | 2008-08-22 | 2009-10-28 | Mechlift Invest Pty Ltd | Data unit for a bin lifting device |
| JP5794917B2 (ja) | 2008-09-12 | 2015-10-14 | アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ | Ｐｄ−１特異抗体およびその使用 |
| MX342017B (es) * | 2010-03-26 | 2016-09-09 | Dartmouth College | Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos. |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| TR201815488T4 (tr) | 2011-04-08 | 2018-11-21 | Health | Anti-epidermal büyüme faktör reseptörü varyant III kimerik antijen reseptörleri ve kanser tedavisi için kullanımı. |
| PH12014500247A1 (en) | 2011-07-29 | 2014-03-24 | Univ Pennsylvania | Switch costimulatory receptors |
| IN2014CN02906A (enExample) | 2011-10-20 | 2015-07-03 | Us Health | |
| US9688740B2 (en) * | 2011-10-26 | 2017-06-27 | National Cancer Center | Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy |
| WO2013062365A2 (ko) * | 2011-10-26 | 2013-05-02 | 국립암센터 | 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물 |
| CA2868121C (en) | 2012-03-23 | 2021-06-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| ES3065694T3 (en) | 2012-04-11 | 2026-05-07 | Us Health | Chimeric antigen receptors targeting b-cell maturation antigen |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| JP6285553B2 (ja) | 2013-08-26 | 2018-02-28 | インノバイオファーム リミテッド | 抗ｃｄ３０キメラ抗原受容体およびその使用 |
| HK1251862A1 (zh) | 2014-12-02 | 2019-04-26 | 普拉斯派克特查特凯尔Rwmc有限责任公司 | 治疗癌症的方法和组合物 |
| CN107531805A (zh) | 2015-03-05 | 2018-01-02 | 弗雷德哈钦森癌症研究中心 | 免疫调节融合蛋白及其用途 |
| CN115927474A (zh) | 2015-06-19 | 2023-04-07 | 塞巴斯蒂安·科博尔德 | Pd-1-cd28融合蛋白及其在医学中的用途 |
| WO2016210129A1 (en) | 2015-06-23 | 2016-12-29 | Memorial Sloan-Kettering Cancer Center | Novel pd-1 immune modulating agents |
| US20180185434A1 (en) | 2015-06-29 | 2018-07-05 | The Johns Hopkins University | Immune checkpoint chimeric antigen receptors therapy |
| US11242375B2 (en) | 2015-09-04 | 2022-02-08 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| US11020429B2 (en) | 2015-11-05 | 2021-06-01 | Juno Therapeutics, Inc. | Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy |
| CN105331585A (zh) | 2015-11-13 | 2016-02-17 | 科济生物医药（上海）有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| US11648268B2 (en) | 2015-12-09 | 2023-05-16 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of using same |
| WO2017162797A1 (en) | 2016-03-23 | 2017-09-28 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of pd-1 and 4-1bb |
| JP2020512284A (ja) | 2016-12-22 | 2020-04-23 | ウィンドミル セラピューティクス インコーポレイテッド | 免疫系調節組成物および方法 |
| CA3071661A1 (en) | 2017-09-06 | 2019-03-14 | Fred Hutchinson Cancer Research Center | Strep-tag specific chimeric receptors and uses thereof |
| CN115418362B (zh) * | 2019-12-02 | 2025-06-13 | 吉林凯莱英医药化学有限公司 | 共固定化酶、其制备方法及其应用 |
-
2016
- 2016-06-20 CN CN202210834160.0A patent/CN115927474A/zh active Pending
- 2016-06-20 JP JP2018517487A patent/JP7085988B2/ja active Active
- 2016-06-20 PT PT167368026T patent/PT3310805T/pt unknown
- 2016-06-20 PL PL16736802T patent/PL3310805T3/pl unknown
- 2016-06-20 ES ES16736802T patent/ES2870174T3/es active Active
- 2016-06-20 EP EP21155542.0A patent/EP3909972B1/en active Active
- 2016-06-20 CN CN202210854297.2A patent/CN115925971A/zh active Pending
- 2016-06-20 DK DK21155542.0T patent/DK3909972T5/da active
- 2016-06-20 ES ES21155542T patent/ES2976647T3/es active Active
- 2016-06-20 DK DK16736802.6T patent/DK3310805T3/da active
- 2016-06-20 FI FIEP21155542.0T patent/FI3909972T3/fi active
- 2016-06-20 EP EP16736802.6A patent/EP3310805B1/en active Active
- 2016-06-20 AU AU2016277883A patent/AU2016277883B2/en active Active
- 2016-06-20 US US15/737,877 patent/US11192935B2/en active Active
- 2016-06-20 CA CA2989949A patent/CA2989949A1/en active Pending
- 2016-06-20 CN CN201680048221.3A patent/CN108026151B/zh active Active
- 2016-06-20 EP EP24156660.3A patent/EP4349854A3/en active Pending
- 2016-06-20 WO PCT/EP2016/064195 patent/WO2016203048A1/en not_active Ceased
- 2016-06-20 HU HUE16736802A patent/HUE054201T2/hu unknown
-
2021
- 2021-10-29 US US17/515,250 patent/US12570718B2/en active Active
-
2022
- 2022-03-22 JP JP2022044885A patent/JP7460675B2/ja active Active
-
2024
- 2024-03-21 JP JP2024044396A patent/JP2024073636A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK3310805T3 (da) | 2021-05-03 |
| PL3310805T3 (pl) | 2021-08-23 |
| CA2989949A1 (en) | 2016-12-22 |
| US11192935B2 (en) | 2021-12-07 |
| FI3909972T3 (fi) | 2024-05-03 |
| EP4349854A2 (en) | 2024-04-10 |
| EP3310805B1 (en) | 2021-02-17 |
| HUE054201T2 (hu) | 2021-08-30 |
| DK3909972T3 (da) | 2024-04-29 |
| CN115927474A (zh) | 2023-04-07 |
| CN108026151A (zh) | 2018-05-11 |
| JP7085988B2 (ja) | 2022-06-17 |
| EP3909972A1 (en) | 2021-11-17 |
| ES2870174T3 (es) | 2021-10-26 |
| DK3909972T5 (da) | 2024-08-05 |
| JP2022084787A (ja) | 2022-06-07 |
| EP3909972B1 (en) | 2024-02-14 |
| US20190010207A1 (en) | 2019-01-10 |
| EP4349854A3 (en) | 2024-07-10 |
| CN115925971A (zh) | 2023-04-07 |
| US12570718B2 (en) | 2026-03-10 |
| US20220169699A1 (en) | 2022-06-02 |
| AU2016277883A8 (en) | 2018-01-25 |
| EP3310805A1 (en) | 2018-04-25 |
| JP2018518990A (ja) | 2018-07-19 |
| CN108026151B (zh) | 2022-07-15 |
| JP7460675B2 (ja) | 2024-04-02 |
| JP2024073636A (ja) | 2024-05-29 |
| AU2016277883A1 (en) | 2018-01-18 |
| WO2016203048A1 (en) | 2016-12-22 |
| AU2016277883B2 (en) | 2020-09-17 |
| ES2976647T3 (es) | 2024-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3310805T3 (pl) | Białka fuzyjne pd-1-cd28 i ich zastosowanie w medycynie | |
| HUS2500022I1 (hu) | Terápiás ellenanyagok és alkalmazásaik | |
| IL258712A (en) | A system for creating a spray and a capsule for use in a system for creating a spray | |
| ZA201801640B (en) | Gitrl fusion proteins and uses thereof | |
| SG10201913807QA (en) | Multivalent and multispecific gitr-binding fusion proteins | |
| SG10201912405TA (en) | Multivalent and multispecific 41bb-binding fusion proteins | |
| ZA201603262B (en) | Interleukin-2 fusion proteins and uses thereof | |
| SG11201707182WA (en) | Immunomodulatory fusion proteins and uses thereof | |
| GB201509062D0 (en) | OX40L fusion proteins and uses thereof | |
| HUE051661T2 (hu) | Készítmények és gyógyászati felhasználások a TCR újraprogramozására fúziós fehérjék felhasználásával | |
| EP3147298A4 (en) | Pd-l1 fusion protein and use thereof | |
| ZA201802002B (en) | Long-acting fgf21 fusion proteins and pharmaceutical composition comprising same | |
| ZA201800238B (en) | Multivalent and multispecific dr5-binding fusion proteins | |
| SI3565828T1 (sl) | SIRP1 alfa-41BBL fuzijski protein in postopki za njegovo uporabo | |
| GB2570063B (en) | Fusion protein and applications thereof | |
| SI3290441T1 (sl) | RGMA-vezavni protein in njegova uporaba | |
| IL251799A0 (en) | Serpin-fused polypeptides and methods of using them | |
| EP3235831A4 (en) | Artificial multi-antigen fusion protein and preparation and use thereof | |
| EP3237452A4 (en) | Fusion proteins and methods thereof | |
| DK3158058T3 (da) | Fusionsproteiner og bruger deraf | |
| EP3029071A4 (en) | Saxatilin-fc fusion protein and use thereof | |
| ZA201608886B (en) | Human cytolytic fusion proteins | |
| TH1601000600A (th) | โปรตีนการเชื่อมหลอมที่ใช้ในการรักษา |